Corrigendum to "Metformin: Still the sweet spot for CV protection in diabetes?" [Curr Opin Pharmacol 54 (2020) 202-208]

Graham Rena; Ify R. Mordi; Chim C. Lang

doi:10.1016/j.coph.2021.03.010

Corrigendum to "Metformin: Still the sweet spot for CV protection in diabetes?" [Curr Opin Pharmacol 54 (2020) 202-208]

Graham Rena (Lead / Corresponding author), Ify R. Mordi (Lead / Corresponding author), Chim C. Lang (Lead / Corresponding author)

Research output: Contribution to journal › Article › peer-review

Abstract

It has come to our attention that figure 1 of our recent article [1], is incorrect. The figure is presented correctly below and where the figure is referred to, the article text should read as follows: “In meta-analysis of recent CVOTs, consistent with a CV-protective effect of metformin, metformin use at baseline is associated with a lower risk of CV death (OR 0.69 95% CI 0.64–0.74), in both the placebo and active drug groups (interaction p value 0.77) (Figure 1)”. The Odds Ratio arising from the analysis is minimally affected by the error and the conclusions of the review unaffected. We apologise for this error. [Figure presented]

Original language	English
Article number	102070
Number of pages	2
Journal	Current Opinion in Pharmacology
Volume	64
Early online date	25 May 2021
DOIs	https://doi.org/10.1016/j.coph.2021.03.010
Publication status	Published - Jun 2022

ASJC Scopus subject areas

Drug Discovery
Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.coph.2021.03.010

Cite this

@article{75bda7946f8a41ee93b7ae8ed685fe21,

title = "Corrigendum to {"}Metformin: Still the sweet spot for CV protection in diabetes?{"} [Curr Opin Pharmacol 54 (2020) 202-208]",

abstract = "It has come to our attention that figure 1 of our recent article [1], is incorrect. The figure is presented correctly below and where the figure is referred to, the article text should read as follows: “In meta-analysis of recent CVOTs, consistent with a CV-protective effect of metformin, metformin use at baseline is associated with a lower risk of CV death (OR 0.69 95% CI 0.64–0.74), in both the placebo and active drug groups (interaction p value 0.77) (Figure 1)”. The Odds Ratio arising from the analysis is minimally affected by the error and the conclusions of the review unaffected. We apologise for this error. [Figure presented]",

author = "Graham Rena and Mordi, {Ify R.} and Lang, {Chim C.}",

note = "{\textcopyright} 2020 Elsevier Ltd",

year = "2022",

month = jun,

doi = "10.1016/j.coph.2021.03.010",

language = "English",

volume = "64",

journal = "Current Opinion in Pharmacology",

issn = "1471-4892",

publisher = "Elsevier",

}

Corrigendum to "Metformin: Still the sweet spot for CV protection in diabetes?" [Curr Opin Pharmacol 54 (2020) 202-208]. / Rena, Graham (Lead / Corresponding author); Mordi, Ify R. (Lead / Corresponding author); Lang, Chim C. (Lead / Corresponding author).
In: Current Opinion in Pharmacology, Vol. 64, 102070, 06.2022.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Corrigendum to "Metformin: Still the sweet spot for CV protection in diabetes?" [Curr Opin Pharmacol 54 (2020) 202-208]

AU - Rena, Graham

AU - Mordi, Ify R.

AU - Lang, Chim C.

PY - 2022/6

Y1 - 2022/6

N2 - It has come to our attention that figure 1 of our recent article [1], is incorrect. The figure is presented correctly below and where the figure is referred to, the article text should read as follows: “In meta-analysis of recent CVOTs, consistent with a CV-protective effect of metformin, metformin use at baseline is associated with a lower risk of CV death (OR 0.69 95% CI 0.64–0.74), in both the placebo and active drug groups (interaction p value 0.77) (Figure 1)”. The Odds Ratio arising from the analysis is minimally affected by the error and the conclusions of the review unaffected. We apologise for this error. [Figure presented]

AB - It has come to our attention that figure 1 of our recent article [1], is incorrect. The figure is presented correctly below and where the figure is referred to, the article text should read as follows: “In meta-analysis of recent CVOTs, consistent with a CV-protective effect of metformin, metformin use at baseline is associated with a lower risk of CV death (OR 0.69 95% CI 0.64–0.74), in both the placebo and active drug groups (interaction p value 0.77) (Figure 1)”. The Odds Ratio arising from the analysis is minimally affected by the error and the conclusions of the review unaffected. We apologise for this error. [Figure presented]

UR - http://www.scopus.com/inward/record.url?scp=85105571692&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2021.03.010

DO - 10.1016/j.coph.2021.03.010

M3 - Article

C2 - 33985901

SN - 1471-4892

VL - 64

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

M1 - 102070

ER -

Corrigendum to "Metformin: Still the sweet spot for CV protection in diabetes?" [Curr Opin Pharmacol 54 (2020) 202-208]

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Metformin: still the sweet spot for CV protection in diabetes?

Cite this